Pharmacogenetics in cardiovascular diseases: State of the art and implementation-recommendations of the French National Network of Pharmacogenetics... - PubMed - NCBI

Pharmacogenetics in cardiovascular diseases: State of the art and implementation-recommendations of the French National Network of Pharmacogenetics... - PubMed - NCBI

• NCBI
• Skip to main content
• Skip to navigation
• Resources
• How To
• About NCBI Accesskeys

Sign in to NCBI

PubMed

US National Library of MedicineNational Institutes of Health

Search databaseAll DatabasesAssemblyBioProjectBioSampleBioSystemsBooksClinVarCloneConserved DomainsdbGaPdbVarESTGeneGenomeGEO DataSetsGEO ProfilesGSSGTRHomoloGeneMedGenMeSHNCBI Web SiteNLM CatalogNucleotideOMIMPMCPopSetProbeProteinProtein ClustersPubChem BioAssayPubChem CompoundPubChem SubstancePubMedPubMed HealthSNPSparcleSRAStructureTaxonomyToolKitToolKitAllToolKitBookToolKitBookghUniGene

Search term

• Advanced
• Help

Result Filters

• Format: Abstract

Send to

Therapie. 2017 Jan 30. pii: S0040-5957(17)30010-0. doi: 10.1016/j.therap.2016.09.017. [Epub ahead of print]

Pharmacogenetics in cardiovascular diseases: State of the art and implementation-recommendations of the French National Network of Pharmacogenetics (RNPGx).

Lamoureux F1, Duflot T2; French Network of Pharmacogenetics (RNPGX).

Author information

Abstract

The use of genomic markers to predict drug response and effectiveness has the potential to improve healthcare by increasing drug efficacy and minimizing adverse effects. Polymorphisms associated with inter-individual variability in drug metabolism, transport, or pharmacodynamics of major cardiovascular drugs have been identified. These include single nucleotide polymorphisms (SNP) affecting clinical outcomes in patients receiving antiplatelet agents, oral anticoagulants and statins. Based on clinical evidence supporting genetic testing in the management of cardiovascular diseases using these drug classes, this short review presents clinical guidance regarding current pharmacogenetics implementation in routine medical practice.

Copyright © 2017 Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. All rights reserved.

KEYWORDS:

Cardiovascular drugs; Clinical implementation; Pharmacogenetics; Pharmacogenomics

PMID:

 

28237404

 

DOI:

 

10.1016/j.therap.2016.09.017

From Guideline Database

This database contains updated guidelines, policies and recommendations on genomic research and practice, as provided by professional organizations, federal advisory groups, expert panels and policy groups.

---

• Pharmacogenetics in cardiovascular diseases: State of the art and implementation-recommendations of the French National Network of Pharmacogenetics (RNPGx).  
  Published 2017 (French National Network of Pharmacogenetics (RNPGx))
• Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results.  
  Published 2008 (International Agency for Research on Cancer (IARC))
• Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation.  
  Published 2017 (CF Foundation) (Expert panel)
• Clinical worthlessness of genetic prediction of common forms of diabetes mellitus and related chronic complications.: A position statement of the Italian Society of Diabetology.  
  Published 2017 (Italian Society of Diabetology)
• [Diagnosis and treatment of familial hypercholesterolemia in Spain: consensus document].  
  Published 2015 (Expert panel)

more